A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Carbidopa, Levodopa and Entacapone

Aromatic Amino Acid class · 3 generic manufacturers · 18 ANDAs filed at FDA.

First FDA approval2021-08-05
Generic availableYes · 3 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.636/unit
6 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.699
Across all dosage forms in distribution.
Highest NADAC
$0.761
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Carbidopa, Levodopa and Entacapone used for?

Carbidopa, Levodopa and Entacapone is a Aromatic Amino Acid medication tracked in Medicare Part D.

Is there a generic for Carbidopa, Levodopa and Entacapone?

Yes. 18 ANDAs filed at FDA, 3 generic manufacturers currently shipping.

How much does my plan pay for Carbidopa, Levodopa and Entacapone?

Across 329 Part D plans, Carbidopa, Levodopa and Entacapone averages $0.699/unit (NADAC). Lowest available: $0.636/unit. Highest in distribution: $0.761/unit.

Is Carbidopa, Levodopa and Entacapone on the FDA shortage list?

No. Carbidopa, Levodopa and Entacapone is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Aromatic Amino Acid2 alternatives in D1
01
Carbidopa and Levodopa
Brand: CREXONT
$0.074Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Levodopa
Brand: Inbrija
Lowest NADAC
0Generic mfrs
$44.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.